{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:35:40Z","timestamp":1786739740544,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>So far, lots of analyses have been conducted to invent the appropriate therapeutic targets for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The category and the strategies for treating the virus are described in this review together with mentioning some specific drugs. Of them, saikosaponin possesses affinity of the drug toward nonstructural protein 15 and the spike glycoprotein of the SARS-CoV-2. The nucleotide inhibitors such as sofosbuvir, ribavirin, galidesivir, remdesivir, favipiravir, cefuroxime, tenofovir, and hydroxychloroquine (HCHL), setrobuvir, YAK, and IDX-184 were found to be effective in binding to SARS-CoV-2 RNA-dependent RNA polymerase. From the antimalarial and anti-inflammatory category, chloroquine and its derivative HCHL have already been approved by the U.S. Food and Drug Administration for emergency treatment of SARS-CoV-2 infection. The other drugs such as favipiravir and lopinavir\/ritonavir under the antiviral category, the angiotensin-converting enzyme 2 (the renin-angiotensin system inhibitors), remdesivir (RNA polymerase inhibitor) from antiviral category, cepharanthine from anti-inflammatory category, etc., have been pointed based on the previous literature published. Besides, the assessment of the drug repositioning candidates with the related targets is also significant for the viral mitigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tcmj.tcmj_100_20","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T03:16:02Z","timestamp":1598325362000},"page":"7-12","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic"],"prefix":"10.4103","volume":"33","author":[{"given":"Rashed","family":"Noor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R4-2-20240828","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.micinf.2020.04.004","article-title":"Chloroquine paradox may cause more damage than help fight COVID-19","volume":"22","author":"Sharma","year":"2020","journal-title":"Microbes Infect"},{"key":"R5-2-20240828","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"R6-2-20240828","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R7-2-20240828","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"key":"R8-2-20240828","doi-asserted-by":"crossref","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin Immunol"},{"key":"R9-2-20240828","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"R10-2-20240828","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/ijp.IJP_115_20","article-title":"Drug targets for corona virus: A systematic review","volume":"52","author":"Prajapat","year":"2020","journal-title":"Indian J Pharmacol"},{"key":"R11-2-20240828","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000503030","article-title":"Innate Immune Evasion by Human Respiratory RNA Viruses","volume":"12","author":"Kikkert","year":"2020","journal-title":"J Innate Immun"},{"key":"R12-2-20240828","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2020.05.003","article-title":"The cytokine storm in COVID-19: An overview of the involvement of the chemokine\/chemokine-receptor system","volume":"53","author":"Coperchini","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"R13-2-20240828","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses Drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"R14-2-20240828","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-2-20240828","doi-asserted-by":"crossref","first-page":"58","DOI":"10.18433\/jpps31002","article-title":"Current drugs with potential for treatment of COVID-19: A literature review","volume":"23","author":"Md Insiat Islam","year":"2020","journal-title":"J Pharm Pharm Sci"},{"key":"R17-2-20240828","doi-asserted-by":"crossref","first-page":"104761","DOI":"10.1016\/j.phrs.2020.104761","article-title":"Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)","volume":"156","author":"Runfeng","year":"2020","journal-title":"Pharmacol Res"},{"key":"R18-2-20240828","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"R19-2-20240828","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/CM9.0000000000000797","article-title":"Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model","volume":"133","author":"Fan","year":"2020","journal-title":"Chin Med J (Engl"},{"key":"R22-2-20240828","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.xkme.2020.03.001","article-title":"Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient","volume":"2","author":"Tang","year":"2020","journal-title":"Kidney Med"},{"key":"R23-2-20240828","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem"},{"key":"R24-2-20240828","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41422-020-0290-0","article-title":"Virus against virus: A potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses","volume":"30","author":"Nguyen","year":"2020","journal-title":"Cell Res"},{"key":"R25-2-20240828","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.3346\/jkms.2020.35.e79","article-title":"Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: The application of lopinavir\/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J Korean Med Sci"},{"key":"R26-2-20240828","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","article-title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","volume":"14","author":"Wang","year":"2020","journal-title":"Biosci Trends"},{"key":"R27-2-20240828","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu Rev Virol"},{"key":"R28-2-20240828","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12688\/f1000research.22211.2","article-title":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China","volume":"9","author":"Kruse","year":"2020","journal-title":"F1000Res"},{"key":"R29-2-20240828","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"R30-2-20240828","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2014a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"R31-2-20240828","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"key":"R32-2-20240828","doi-asserted-by":"crossref","first-page":"e1000511","DOI":"10.1371\/journal.ppat.1000511","article-title":"Structure and inhibition of the SARS coronavirus envelope protein ion channel","volume":"5","author":"Pervushin","year":"2009","journal-title":"PLoS Pathog"},{"key":"R33-2-20240828","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1016\/j.vaccine.2007.05.025","article-title":"Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope","volume":"25","author":"Cheung","year":"2007","journal-title":"Vaccine"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_100_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:32:08Z","timestamp":1786735928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_100_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_100_20","relation":{},"ISSN":["1016-3190"],"issn-type":[{"value":"1016-3190","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}